Prima Biomed (PRR.AX) To Present At Upcoming Investor Forums In New York
2/27/2014 8:01:19 AM
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”, “the Company”)
will present a corporate overview and provide an update of its CVac™ development program at
the 24th Annual Wall Street Analyst Forum Institutional Investor Conference at the University
Club in New York City on Monday, March 3rd at 1:35 p.m. (U.S. Eastern Standard Time).
At the time of the presentation, a live webcast of Prima's presentation will be available at the
following link: www.visualwebcaster.com/event.asp?id=98054.
After the presentation, an archived version of the webcast will be available on Prima’s website
About Prima BioMed
Prima BioMed is a globally active leader in the development of personalized immunocellular
therapeutic products for the treatment of cancer. Prima is dedicated to leveraging its
technology and expertise to bring innovative treatment options to market for patients and to
maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cellbased
product currently in clinical trials. www.primabiomed.com.au
About the Wall Street Analyst Forum Institutional Investor Conference
Since 1989, The Wall Street Analyst Forum has sponsored over 80 analyst conferences for
NYSE/NASDAQ/AMEX corporations in New York, Boston & London. Over 2,200 different public
corporations have presented and analysts & portfolio managers from over 2000
different institutions have attended in person & via webcast.
For further information please contact:
Ms. Jessica Brown, Prima BioMed Ltd.
+1 (919) 710-9061; email@example.com
Mr. James Moses, Mandate Corporate
+61 (0) 420 991 574; firstname.lastname@example.org
Mr. Axel Mühlhaus, edicto GmbH
+49 (0) 69 905505-52; email@example.com
Help employers find you! Check out all the jobs and post your resume.
comments powered by